Status:
RECRUITING
A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
Lead Sponsor:
Maastricht Radiation Oncology
Collaborating Sponsors:
Maastricht University Medical Center
Zuyderland Medisch Centrum
Conditions:
Low-grade Glioma
High Grade Glioma
Eligibility:
All Genders
18+ years
Brief Summary
There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the c...
Detailed Description
To establish primary patient-derived three-dimensional organoid cultures from low grade and high-grade gliomas to study the mechanisms that contribute to i.e. resistance to radiotherapy and/or chemot...
Eligibility Criteria
Inclusion
- MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)
- Age 18 years or older
- Patient is eligible for a resection of the tumor
Exclusion
- Contra-inidication for neurosurgical resection of the tumor.
- Incapacitated patient, unable to give informed consent.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04865315
Start Date
May 1 2022
End Date
December 1 2028
Last Update
September 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht Radiation Oncology
Maastricht, Limburg, Netherlands, 6229ET